Cargando…
Real-world Outcomes, Treatment Patterns and T790M Testing Rates in Non-small Cell Lung Cancer Patients Treated with First-line First- or Second-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors from the Slovenian Cohort of the REFLECT Study
BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC). However, routine clinical practice is different between countries/institutions. PATIENTS AND METHODS: The REFLECT stud...
Autores principales: | Turnsek, Nina, Devjak, Rok, Edelbaher, Natalija, Osrajnik, Ilonka, Unk, Mojca, Vidovic, Dusanka, Jeric, Tina, Janzic, Urska |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sciendo
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400443/ https://www.ncbi.nlm.nih.gov/pubmed/35853681 http://dx.doi.org/10.2478/raon-2022-0025 |
Ejemplares similares
-
The impact of the COVID-19 pandemic on organised cervical cancer screening: The first results of the Slovenian cervical screening programme and registry
por: Ivanuš, Urška, et al.
Publicado: (2021) -
Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
por: Chai, Chee-Shee, et al.
Publicado: (2020) -
Temperatures and storage conditions in domestic refrigerators - Slovenian scenario
por: Ovca, Andrej, et al.
Publicado: (2021) -
The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2018) -
T790M mutations identified by circulating tumor DNA test in lung adenocarcinoma patients who progressed on first-line epidermal growth factor receptor-tyrosine kinase inhibitors
por: Merinda, Vinodini, et al.
Publicado: (2020)